Cargando…

A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

INTRODUCTION: Bevacizumab and gemcitabine are key drugs for treating recurrent epithelial ovarian cancer. However, information about the combination of bevacizumab and gemcitabine is insufficient. We conducted a phase II study to assess the feasibility, clinical activity, and toxicity of this combin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nagao, Shoji, Kogiku, Ai, Suzuki, Kazuhiro, Shibutani, Takashi, Yamamoto, Kasumi, Jimi, Tomoatsu, Kitai, Miho, Shiozaki, Takaya, Matsuoka, Kazuko, Yamaguchi, Satoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7006142/ https://www.ncbi.nlm.nih.gov/pubmed/32028974 http://dx.doi.org/10.1186/s13048-020-0617-y

Ejemplares similares

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: The Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2021)

Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer
por: Roque, Dana M., et al.
Publicado: (2022)

Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers
por: Martin, Jovana Y., et al.
Publicado: (2016)

Paraganglioma of the Fallopian Tube Presenting as Isolated Fallopian Tube Torsion
por: Takeda, Akihiro, et al.
Publicado: (2022)

Endometrial carcinoma in a 14-year-old: A case report
por: Uda, Hajime, et al.
Publicado: (2019)

An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023
por: Shoji, Tadahiro, et al.
Publicado: (2018)

Aggressive surgery could overcome the extent of initial peritoneal dissemination for advanced ovarian, fallopian tube, and peritoneal carcinoma
por: Nishikimi, Kyoko, et al.
Publicado: (2020)

Peritoneal Dialysis Catheter−Fallopian Tube Fistula
por: Mandalapu, Rajendra, et al.
Publicado: (2020)

Successful Endoscopic Treatment for High-grade Cervical Intraepithelial Neoplasia with Gross Lesions of the Vagina
por: Yamamoto, Koyo, et al.
Publicado: (2021)

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
por: Fu, Siqing, et al.
Publicado: (2022)

Outcomes and Prognostic Factors of Patients with Platinum-Resistant or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer and Peritoneal Cancer
por: Hamontri, Suttha, et al.
Publicado: (2023)

Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
por: Cohen, Samantha, et al.
Publicado: (2019)

Complete remission of platinum-refractory primary Fallopian tube carcinoma with third-line gemcitabine plus cisplatin: A case report and review of the literature
por: XU, QIUYI, et al.
Publicado: (2013)

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study
por: Ghezelayagh, Talayeh S., et al.
Publicado: (2023)

Tumorigenesis and peritoneal colonization from fallopian tube epithelium
por: Eddie, Sharon L., et al.
Publicado: (2015)

Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
por: Pecorelli, S., et al.
Publicado: (2010)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Liao, John B, et al.
Publicado: (2021)

Potential predictors for chemotherapeutic response and prognosis in epithelial ovarian, fallopian tube and primary peritoneal cancer patients treated with platinum-based chemotherapy
por: Jeerakornpassawat, Dhammapoj, et al.
Publicado: (2020)

Discussing maintenance therapy for ovarian, peritoneal, and fallopian tube cancers
por: Mercier, Ann Marie, et al.
Publicado: (2023)

Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial
por: Tate, Shinichi, et al.
Publicado: (2020)

Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2020)

Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review
por: Zagouri, Flora, et al.
Publicado: (2015)

Duplication of the fallopian tube
por: R, Narayanan, et al.
Publicado: (2008)

Diseases of the Fallopian Tubes
Publicado: (1885)

A Contribution to the Study of Hernias of the Ovary, of the Fallopian Tube and of the Ovary and Fallopian Tube
por: Heineck, Aime Paul
Publicado: (1916)

Incidence of gastrointestinal perforation associated with bevacizumab in combination with neoadjuvant chemotherapy as first-line treatment of advanced ovarian, fallopian tube, or peritoneal cancer: analysis of a Japanese healthcare claims database
por: Ueda, Akihiko, et al.
Publicado: (2022)

Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
por: Kotaka, Saki, et al.
Publicado: (2023)

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)
por: Lee, Elizabeth K., et al.
Publicado: (2020)

Extraskeletal chondroma of the fallopian tube.
por: Han, Jee-Young, et al.
Publicado: (2002)

Posthysterectomy fallopian tube prolapse
por: Sanklecha, Vandana M, et al.
Publicado: (2012)

Hydatid Cyst of Fallopian Tube
por: Jafarian, A, et al.
Publicado: (2014)

Isolated Fallopian Tube Torsion
por: Kardakis, S., et al.
Publicado: (2013)

Development of the Placenta in the Fallopian Tube
por: Andrews, C. N.
Publicado: (1853)

Morbid Anatomy of the Fallopian Tubes
Publicado: (1887)

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers
por: Vasey, P A, et al.
Publicado: (2008)

Safety and Efficacy of Video Laparoscopic Surgical Debulking of Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
por: Nezhat, Farr R., et al.
Publicado: (2012)

Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study
por: Park, Soo Jin, et al.
Publicado: (2019)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Factors Affecting Pregnancy Rate Following Fallopian Tube Recanalization in Women with Proximal Fallopian Tube Obstruction
por: Al-Omari, Mamoon H., et al.
Publicado: (2018)

Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Müllerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group
por: Katsumata, Noriyuki, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_58f1ahdrlvpu49qgo1ho9f0obp